FDA officials are pondering whether the use of patients’ own baseline liver enzyme data prior to entering a clinical trial may be the preferable way to monitor for drug-induced liver injury in studies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?